ArticleScientific reports2016
Immune Responses to an Oral Cholera Vaccine in Internally Displaced Persons in South Sudan.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Delivering infectious disease interventions to women and children in conflict settings: a systematic reviefw.BMJ global health · 2020Pooled it
- An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon.The American journal of tropical medicine and hygiene · 2022Trial
- Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.Human vaccines & immunotherapeutics · 2018Trial
- Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.Human vaccines & immunotherapeutics · 2017Trial
- Oral cholera vaccine uptake, acceptance and confidence among residents of a high-risk township in Zambia: key insights for future vaccination programs.International health · 2026Article
- Statistical Modelling of Waning Immunity After Shanchol™ Vaccination: A Prospective Cohort Study.Vaccines · 2026Article
- Article
- Diagnosis, Management, and Future Control of Cholera.Clinical microbiology reviews · 2022Review
- Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia.PloS one · 2022Article
- Cholera Hot-Spots and Contextual Factors in Burundi, Planning for Elimination.Tropical medicine and infectious disease · 2021Article
- The long-run heterogeneous effects of a cholera pandemic on stature: Evidence from industrializing Japan.Economics and human biology · 2021Article
- Reactive mass vaccination campaign against cholera in the COVID-19 context in Cameroon: challenges, best practices and lessons learned.The Pan African medical journal · 2021Article
- The health of internally displaced children in sub-Saharan Africa: a scoping review.BMJ global health · 2020Article
- The multi-sectorial emergency response to a cholera outbreak in Internally Displaced Persons camps in Borno State, Nigeria, 2017.BMJ global health · 2020Article
- Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba.PLoS neglected tropical diseases · 2019Article
- Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.PLoS neglected tropical diseases · 2019Article
- Long-run effects of early childhood exposure to cholera on final height: Evidence from industrializing Japan.SSM - population health · 2018Article
- High Prevalence ofThe American journal of tropical medicine and hygiene · 2018Article
- Dried Blood Spots for Measuring Vibrio cholerae-specific Immune Responses.PLoS neglected tropical diseases · 2018Article
- High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan.The American journal of tropical medicine and hygiene · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 4 countries.
Funding
Abstract
Despite recent large-scale cholera outbreaks, little is known about the immunogenicity of oral cholera vaccines (OCV) in African populations, particularly among those at highest cholera risk. During a 2015 preemptive OCV campaign among internally displaced persons in South Sudan, a year after a large cholera outbreak, we enrolled 37 young children (1-5 years old), 67 older children (6-17 years old) and 101 adults (≥18 years old), who received two doses of OCV (Shanchol) spaced approximately 3 weeks apart. Cholera-specific antibody responses were determined at days 0, 21 and 35 post-immunization. High baseline vibriocidal titers (>80) were observed in 21% of the participants, suggesting recent cholera exposure or vaccination. Among those with titers ≤80, 90% young children, 73% older children and 72% adults seroconverted (≥4 fold titer rise) after the 1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.